- GlobeNewswire•3 months agoClinical Leaders Reinforce Belief in NGAL for Detection of AKI Following FDA's Decision on BioPorto's The NGAL TestTM
Copenhagen -- In response to the recent FDA decision to decline BioPorto's initial submission for the kidney biomarker neutrophil gelatinase-associated lipocalin (NGAL) as the first diagnostic aid for ...
We're sorry this is all we were able to find about this topic.
BioPorto A/S (BIOPOR.CO)
Copenhagen - Copenhagen Delayed Price. Currency in DKK
|Day's Range||2.22 - 2.23|
|52wk Range||1.40 - 5.40|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-17.84|
|Avg Vol (3m)||851,252|
|Dividend & Yield||N/A (N/A)|